Learn more about our oncolytic immunotherapies and how to enroll in our clinical trials.
At Replimune, we are developing an emerging class of cancer treatments called oncolytic immunotherapies.
Oncolytic immunotherapy has the potential to treat patients with a variety of tumor types and improve on existing immunotherapies. Our goal is to revolutionize cancer treatment by making personalized therapy a practical reality for all patients.
What is oncolytic immunotherapy?
Oncolytic immunotherapy uses viruses that have been modified to selectively replicate in and kill tumors. These therapies are designed to fight cancer in two ways:
1. Directly kill tumors at the site of injection
2. Activate the immune system to kill cancer cells anywhere in the body
How is oncolytic immunotherapy administered?
Oncolytic immunotherapy is given as an intra-tumoral (IT) injection. This means that the immunotherapy is injected directly into some or all of the tumors depending on size and how many tumors are present.
Check out the videos below to learn more about how oncolytic immunotherapy is administered.
Ongoing Clinical Trials
Clinical trials are the research studies intended to find out if a new treatment is safe and provides better outcomes than the existing standard of care–the best available known treatment. Our clinical programs are designed to evaluate the safety and effectiveness of our investigational therapies in a range of solid tumors as single agents and combination with other immunotherapies. Prior research has shown that oncolytic immunotherapy may be able to increase the effectiveness of some other cancer therapies by activating the immune system to fight cancer.
The safety of our patients is a top priority. We conduct our clinical trials with the highest possible standards. Replimune is also closely monitoring the ongoing COVID-19 pandemic to ensure patient safety.
You can find more information about our ongoing clinical trials below. If you are a patient and have questions about whether you are eligible for a clinical trial, please talk to your doctor.